Airway Inflammatory Pathways Regulating Glucocorticoid Receptor Phosphorylation
气道炎症途径调节糖皮质激素受体磷酸化
基本信息
- 批准号:10622111
- 负责人:
- 金额:$ 27.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-03-01 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
PROJECT SUMMARY
Increased airway smooth muscle (ASM) mass, a major feature of airway remodeling in asthma,
profoundly contributes to asthma morbidity, mortality, and pathogenesis. This increased mass is due in
large part to enhanced proliferative activity of ASM cells. Unfortunately, proliferation of these latter cells is
unaffected by current asthma medications, as the process appears to be insensitive to glucocorticoid (GC)
effects. While research aimed at understanding the basis of GC insensitivity (GCI) has focused on the role of
immune cells, few investigators have studied GCI in ASM cells, the pivotal cell regulating bronchomotor tone.
The long-term goal of this research is to identify factors that impair the sensitivity of the ASM proliferative
response to GC in patients with asthma, with the ultimately goal of establishing therapeutic strategies to
circumvent GCI. The current proposal will examine the cellular and molecular mechanisms by which growth
factors (GFs) modulate ASM sensitivity to GCs. Using unique cellular models of ASM cells derived from patients
with asthma, our exciting preliminary data supports the central hypothesis that GF-induced abnormal site-specific
phosphorylation of glucocorticoid receptor (GR) impairs ASM sensitivity to GC. These data now suggest that
(previously unappreciated) GR phosphorylation at serine 134 (ser134) residue inhibits GR signaling. These data
also suggest that GF-induced activation of serine/threonine kinase protein kinase B (PKB/Akt) and
serine/threonine protein phosphatase 2A (PP2A) regulates GR-ser134 phosphorylation. The rationale for the
proposed research is that understanding the interplay among GR signaling and GF-induced kinases and/or
phosphatases may uncover critical information for the development of novel therapeutics to overcome GCI in
asthma. Our hypotheses will be tested by pursuing four specific aims: to identify the functional consequences of
GF-induced abnormal GR site-specific phosphorylation on GR signaling (Aim 1); to characterize the contribution
of kinases and phosphatases to GF-induced abnormal GR site-specific phosphorylation (Aim 2); and to elucidate
the role of steroid-target genes in modulating GC anti-proliferative effects in ASM cells (Aim 3). To this end, we
generated tools (antibody, mutated constructs) to examine the role of GR-ser134 phosphorylation. In all aims,
pharmacological inhibitors, mutated constructs, siRNA, and expression vectors will be used to modulate the
expression of steroid co-repressor, kinases, phosphatases, and steroid-target genes, after which GR site-specific
phosphorylation, GR-mediated transactivation activities and sub-cellular localization, and ASM growth will be
analyzed using state-of-the-art approaches already established in our laboratories. We will also determine the
clinical significance of our in vitro observations by examining whether the aforementioned pathways are activated
in tissues using endobronchial biopsies from subjects both with and without asthma (Aim 4). This integrated
translational approach is expected to advance our understanding of the mechanisms that contribute to the
development of GCI in some patients with asthma.
项目总结
哮喘气道重塑的一个主要特征,即气道平滑肌(ASM)质量增加,
对哮喘的发病率、死亡率和发病机制有着深远的影响。这一增加的质量是由于
很大程度上是由于ASM细胞增殖活性增强所致。不幸的是,后一类细胞的增殖
不受当前哮喘药物的影响,因为这一过程似乎对糖皮质激素(GC)不敏感
效果。虽然旨在了解GC不敏感(GCI)基础的研究主要集中在
在免疫细胞方面,很少有研究人员研究ASM细胞中的GCI,ASM细胞是调节支气管运动张力的关键细胞。
这项研究的长期目标是确定影响ASM增殖剂敏感性的因素
哮喘患者对GC的反应,最终目标是建立治疗策略
绕过GCI。目前的提案将研究生长的细胞和分子机制
因子(GFS)调节ASM对GCs的敏感性。使用来自患者的ASM细胞的独特细胞模型
对于哮喘,我们令人兴奋的初步数据支持了中心假设,即GF诱导的异常部位特异性
糖皮质激素受体(GR)的磷酸化降低ASM对GC的敏感性。这些数据现在表明
丝氨酸134(Ser134)残基的GR磷酸化抑制GR信号转导。这些数据
也提示GF诱导丝氨酸/苏氨酸激酶蛋白激酶B(PKB/Akt)和
丝氨酸/苏氨酸蛋白磷酸酶2A(PP2A)调节GR-Ser134的磷酸化。该计划的基本原理
建议的研究是了解GR信号和GF诱导的激酶和/或
磷酸酶可能为克服GCI的新疗法的开发提供关键信息
哮喘。我们的假设将通过追求四个具体目标来检验:确定
生长因子诱导GR信号的GR位点特异性异常磷酸化(目标1);以表征其作用
激酶和磷酸酶对生长因子诱导的GR位点特异性异常磷酸化的影响(AIM 2);并阐明
类固醇靶基因在调节ASM细胞中GC抗增殖效应中的作用(目标3)。为此,我们
生成的工具(抗体、突变的构建体)用于检测GR-ser134磷酸化的作用。在所有目标中,
药物抑制剂、突变的构建体、siRNA和表达载体将被用来调节
类固醇共抑制因子、激酶、磷酸酶和类固醇靶基因的表达,之后GR位点特异性
磷酸化、GR介导的反式激活活性和亚细胞定位以及ASM生长
使用我们实验室已经建立的最先进的方法进行分析。我们还将确定
检测上述通路是否被激活的体外观察的临床意义
使用来自哮喘患者和非哮喘患者的支气管内活检的组织(目标4)。这一集成
翻译方法有望促进我们对有助于
部分哮喘患者GCI的发生。
项目成果
期刊论文数量(12)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Paucigranulocytic asthma: Uncoupling of airway obstruction from inflammation.
- DOI:10.1016/j.jaci.2018.06.008
- 发表时间:2019-04
- 期刊:
- 影响因子:0
- 作者:Tliba O;Panettieri RA Jr
- 通讯作者:Panettieri RA Jr
Functional KCa3.1 channels regulate steroid insensitivity in bronchial smooth muscle cells.
- DOI:10.4049/jimmunol.1300104
- 发表时间:2013-09-01
- 期刊:
- 影响因子:0
- 作者:Chachi L;Shikotra A;Duffy SM;Tliba O;Brightling C;Bradding P;Amrani Y
- 通讯作者:Amrani Y
Adiponectin/AdipoR1 Axis Promotes IL-10 Release by Human Regulatory T Cells.
- DOI:10.3389/fimmu.2021.677550
- 发表时间:2021
- 期刊:
- 影响因子:7.3
- 作者:Ramos-Ramírez P;Malmhäll C;Tliba O;Rådinger M;Bossios A
- 通讯作者:Bossios A
Protein phosphatase 5 mediates corticosteroid insensitivity in airway smooth muscle in patients with severe asthma.
蛋白质磷酸酶5介导严重哮喘患者气道平滑肌的皮质类固醇不敏。
- DOI:10.1111/all.13003
- 发表时间:2017-01
- 期刊:
- 影响因子:12.4
- 作者:Chachi L;Abbasian M;Gavrila A;Alzahrani A;Tliba O;Bradding P;Wardlaw AJ;Brightling C;Amrani Y
- 通讯作者:Amrani Y
Glucocorticoid Insensitivity in Asthma: The Unique Role for Airway Smooth Muscle Cells.
- DOI:10.3390/ijms23168966
- 发表时间:2022-08-11
- 期刊:
- 影响因子:5.6
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
OMAR TLIBA其他文献
OMAR TLIBA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('OMAR TLIBA', 18)}}的其他基金
Airway Inflammatory Pathways Regulating Glucocorticoid Receptor Phosphorylation
气道炎症途径调节糖皮质激素受体磷酸化
- 批准号:
10159949 - 财政年份:2018
- 资助金额:
$ 27.11万 - 项目类别:
TRUSS as a novel regulator of inflammatory genes in asthma
TRUSS 作为哮喘炎症基因的新型调节剂
- 批准号:
8897989 - 财政年份:2014
- 资助金额:
$ 27.11万 - 项目类别:
TRUSS as a novel regulator of inflammatory genes in asthma
TRUSS 作为哮喘炎症基因的新型调节剂
- 批准号:
8702540 - 财政年份:2014
- 资助金额:
$ 27.11万 - 项目类别:
Airway Inflammatory Pathways Regulating Glucocorticoid Receptor Phosphorylation
气道炎症途径调节糖皮质激素受体磷酸化
- 批准号:
8427314 - 财政年份:2012
- 资助金额:
$ 27.11万 - 项目类别:
Airway Inflammatory Pathways Regulating Glucocorticoid Receptor Phosphorylation
气道炎症途径调节糖皮质激素受体磷酸化
- 批准号:
9424454 - 财政年份:2012
- 资助金额:
$ 27.11万 - 项目类别:
Airway Inflammatory Pathways Regulating Glucocorticoid Receptor Phosphorylation
气道炎症途径调节糖皮质激素受体磷酸化
- 批准号:
8220499 - 财政年份:2012
- 资助金额:
$ 27.11万 - 项目类别:
Airway Inflammatory Pathways Regulating Glucocorticoid Receptor Phosphorylation
气道炎症途径调节糖皮质激素受体磷酸化
- 批准号:
8625331 - 财政年份:2012
- 资助金额:
$ 27.11万 - 项目类别:
Mechanisms of Steroid Resistance in Airway Smooth Muscle Cells
气道平滑肌细胞类固醇抵抗机制
- 批准号:
7753874 - 财政年份:2007
- 资助金额:
$ 27.11万 - 项目类别:
Mechanism of inflammation-induced steroid resistance
炎症诱导类固醇抵抗的机制
- 批准号:
7486327 - 财政年份:2007
- 资助金额:
$ 27.11万 - 项目类别:
Mechanisms of Steroid Resistance in Airway Smooth Muscle Cells
气道平滑肌细胞类固醇抵抗机制
- 批准号:
7684321 - 财政年份:2007
- 资助金额:
$ 27.11万 - 项目类别:
相似海外基金
Exploring the role of bioactive lipids in cell death pathways underpinning inflammatory skin disease
探索生物活性脂质在炎症性皮肤病细胞死亡途径中的作用
- 批准号:
2899550 - 财政年份:2023
- 资助金额:
$ 27.11万 - 项目类别:
Studentship
Inflammatory and fibrotic pathways in lung fibrosis: cross-talk and targeting within a gal-3-fibrosome
肺纤维化中的炎症和纤维化途径:gal-3-纤维体内的串扰和靶向
- 批准号:
2882282 - 财政年份:2023
- 资助金额:
$ 27.11万 - 项目类别:
Studentship
Metabolic and Inflammatory Pathways Linking Adiposity to Cognitive Decline : the Canadian Alliance of Healthy Hearts and Minds Biomarker Study
将肥胖与认知能力下降联系起来的代谢和炎症途径:加拿大健康心智生物标志物研究联盟
- 批准号:
486742 - 财政年份:2023
- 资助金额:
$ 27.11万 - 项目类别:
Operating Grants
Inflammatory pathways via innate immunity in resident renal cells and their regulation against the development of kidney injury
常驻肾细胞中通过先天免疫的炎症途径及其对肾损伤发展的调节
- 批准号:
22K07862 - 财政年份:2022
- 资助金额:
$ 27.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigating the impact of distinct pandemic prenatal stressors on early immune disruptions in children via alterations to prenatal inflammatory pathways
通过改变产前炎症途径来研究不同的大流行性产前应激源对儿童早期免疫破坏的影响
- 批准号:
472158 - 财政年份:2022
- 资助金额:
$ 27.11万 - 项目类别:
Fellowship Programs
Targeting inflammatory and neurodegenerative pathways relevant to progression in the NR1H3 (LXRA) R415Q model of primary progressive multiple sclerosis
靶向与原发性进行性多发性硬化症 NR1H3 (LXRA) R415Q 模型进展相关的炎症和神经退行性通路
- 批准号:
462072 - 财政年份:2022
- 资助金额:
$ 27.11万 - 项目类别:
Operating Grants
Investigating novel targets and inflammatory pathways of cognitive decline in the CLSA
调查里昂证券认知能力下降的新靶点和炎症途径
- 批准号:
481308 - 财政年份:2022
- 资助金额:
$ 27.11万 - 项目类别:
Operating Grants
Integrative analysis of multi-omics data to delineate CCL2 associated inflammatory pathways in Alzheimers Disease
多组学数据综合分析以描绘阿尔茨海默病中 CCL2 相关炎症通路
- 批准号:
10369676 - 财政年份:2021
- 资助金额:
$ 27.11万 - 项目类别:
Targeting innate immune pathways, and inflammatory cell death in cytokine-mediated diseases
针对细胞因子介导疾病中的先天免疫途径和炎症细胞死亡
- 批准号:
10622511 - 财政年份:2021
- 资助金额:
$ 27.11万 - 项目类别:
Subsets of subsets: investigating Th17 pathways in inflammatory bowel disease and HIV
子集的子集:研究炎症性肠病和 HIV 中的 Th17 通路
- 批准号:
448637 - 财政年份:2021
- 资助金额:
$ 27.11万 - 项目类别:
Operating Grants